FierceBiotech5h
Roche nets clearances for sexually transmitted infection tests at the point of care
Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. | The company’s cobas ...
Hosted on MSN5h
Roche’s STI assay panels gain FDA 510(k) clearance and CLIA waiver
Leveraging gold-standard PCR technology, the cobas liat system claims to deliver outcomes in under 20 minutes.
BioPharma Dive7d
Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.
Pharm Exec1d
FDA Grants 510(k) Clearance to Roche’s Cobas Liat Molecular Test for Sexually Transmitted Infections
The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...
Fire and ice a big problem for Worcester firefighters as temperatures drop near zero
Firefighters in Worcester, Massachusetts had to deal with extreme heat and cold Wednesday morning as temperatures dropped to ...
ENDPOINTS NEWS7d
Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s
The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...
Taiwan News1d
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to ...